The cost effectiveness of vaccinating against Lyme disease.

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Meltzer, M. I. ; Dennis, D. T. ; Orloski, K. A.
• Description:
  To determine the cost effectiveness of vaccinating against Lyme disease, we used a decision tree to examine the impact on society of six key components. The main measure of outcome was the cost per case averted. Assuming a 0.80 probability of diagnosing and treating early Lyme disease, a 0.005 probability of contracting Lyme disease, and a vaccination cost of $50 per year, the mean cost of vaccination per case averted was $4,466. When we increased the probability of contracting Lyme disease to 0.03 and the cost of vaccination to $100 per year, the mean net savings per case averted was $3,377. Since few communities have average annual incidences of Lyme disease >0. 005, economic benefits will be greatest when vaccination is used on the basis of individual risk, specifically, in persons whose probability of contracting Lyme disease is >0.01.
• Subjects:
  Antigens, Surface Bacterial Outer Membrane Proteins Bacterial Vaccines Borrelia Burgdorferi Group Cost-Benefit Analysis Decision Trees Humans Lipoproteins Lyme Disease Probability Research Article Vaccination

  More +
• Source:
  Emerg Infect Dis. 5(3):321-328.
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Location:
  North America
• Volume:
  5
• Issue:
  3
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:e642656ac8ee186a0d15b4e69095d0be6070ee49100d825fec657a9f908211e4
• Download URL:
  https://stacks.cdc.gov/view/cdc/3257/cdc_3257_DS1.pdf
• File Type:
  [PDF - 109.74 KB ]